Demographics (3)
- sex - Sex (phv00266724.v3.p1)
- SEX - Sex (phv00266719.v3.p1)
- SEX - Sex (phv00492316.v1.p1)
Race and Ethnicity (1)
- race - Self-reported race (phv00266725.v3.p1)
Respiratory (5)
- blfevprd - Fev1 at dx pft (L/min) (phv00492318.v1.p1)
- blfvcprd - Fvc at dx pft (L/min) (phv00492320.v1.p1)
- blperfev - Fev1 % predicted at dx pft (phv00492319.v1.p1)
- blperfvc - Fvc % predicted at dx pft (phv00492321.v1.p1)
- blratio1 - Fev1/fvc % predicted at dx pft (phv00492322.v1.p1)
Other (21)
- ANALYTE_TYPE - Analyte Type (phv00266728.v3.p1)
- BODY_SITE - Body site where sample was collected (phv00396562.v3.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body. (phv00266713.v3.p1)
- FAMILY_ID - Family ID (phv00266716.v3.p1)
- FATHER - Father's Subject ID (phv00266717.v3.p1)
- Funding_Source - Project funding source (phv00396563.v3.p1)
- IS_TUMOR - Tumor status (phv00426916.v2.p1)
- MOTHER - Mother's Subject ID (phv00266718.v3.p1)
- q11type - Scadding stage at follow-up chest X-ray (based on study criteria) (phv00492324.v1.p1)
- q8type - Scadding stage at first chest X-ray (based on study criteria) (phv00492323.v1.p1)
- SAMPLE_ID - Sample ID (phv00266727.v3.p1)
- SAMPLE_ID - Sample ID (phv00266721.v3.p1)
- SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00266729.v3.p1)
- study_classification - Sarcoidosis status (phv00492317.v1.p1)
- Study_Name - TOPMed-assigned short study name (1:1 with TOPMed phs number) (phv00396566.v3.p1)
- SUBJECT_ID - De-identified Subject ID (phv00266723.v3.p1)
- SUBJECT_ID - Unique Subject ID (phv00266715.v3.p1)
- SUBJECT_ID - Subject ID (phv00266712.v3.p1)
- SUBJECT_ID - Subject ID (phv00266720.v3.p1)
- TOPMed_Phase - TOPMed Phase (phv00396564.v3.p1)
- TOPMed_Project - TOPMed Project that funded sequencing (phv00396565.v3.p1)